Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.GMTX · Entity 2273 | Director · 10% owner | October 04, 2021 | October 06, 2021 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | August 13, 2026 | August 17, 2026 |
| Replimune Group, Inc.REPL · Entity 4707 | Director | April 01, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date October 04, 2021 · Filed October 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2031-10-03 | Direct | 17,245 |
Reported balance
After 2021-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-04 · Grant · Acquired 17,245 · Balance 17,245 F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date. F2: This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date.
F2: This option was granted to the Reporting Person, a director of the Issuer and a member of Atlas Venture Life Science Advisors, LLC ("Atlas"). The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Dyne Therapeutics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,801,128 |
Reported balance
After 2026-08-13 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-08-13 · Sale · Disposed 268,354 · Balance 3,801,128 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,045,735 |
Reported balance
After 2026-08-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2026-08-13 · Sale · Disposed 94,415 · Balance 1,045,735 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). F4: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 751,411 |
Reported balance
After 2026-08-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2026-08-13 · Sale · Disposed 63,643 · Balance 751,411 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6). F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,441,454 |
Reported balance
After 2026-08-14 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-08-14 · Sale · Disposed 1,359,674 · Balance 2,441,454 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive. F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 567,358 |
Reported balance
After 2026-08-14 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2026-08-14 · Sale · Disposed 478,377 · Balance 567,358 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive. F4: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 428,946 |
Reported balance
After 2026-08-14 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2026-08-14 · Sale · Disposed 322,465 · Balance 428,946 F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026. F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive. F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,962 |
Reported balance
Holding disclosure · report date 2026-08-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,962 F7: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026.
F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in footnotes (2) and (6).
F3: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any.
F4: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any.
F5: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive.
F7: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any.
Replimune Group, Inc.
Report date April 01, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2032-04-01 | Direct | 16,500 |
Reported balance
After 2022-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-01 · Grant · Acquired 16,500 · Balance 16,500 F1: This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023. F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on April 1, 2022 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2023.
F2: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Generation Bio Co.
Report date February 09, 2026 · Filed February 09, 2026
Section 16 reporting ended · disclosed 2026-02-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-09 · Other · Disposed 711,193 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-09 · Other · Disposed 116,693 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-09 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-02-09 · Other · Disposed 60 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5: The shares are held directly by Atlas Venture Associates Opportunity I, L.P. ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-09 · Disposition to issuer · Disposed 3,000 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $190.00 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-09 · Disposition to issuer · Disposed 5,200 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $265.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-09 · Disposition to issuer · Disposed 1,500 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.90 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-09 · Disposition to issuer · Disposed 1,920 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-09 · Disposition to issuer · Disposed 2,500 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.20 | Direct | 0 |
Reported balance
After 2026-02-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-09 · Disposition to issuer · Disposed 6,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),
F2: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F3: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
F4: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
F5: The shares are held directly by Atlas Venture Associates Opportunity I, L.P. ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any.
F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time.
F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2026 Filed Apr 30, 2026 21:22 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 119,115 | $18.38 | $2,189,333.70 |
DisclosureSEC source: 0001577014-26-000006 · form4-04302026_090407.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 4,939,489 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 21:22 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 59,870 | $18.38 | $1,100,410.60 |
DisclosureSEC source: 0001577014-26-000006 · form4-04302026_090407.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,577,432 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 35,947 | $18.15 | $652,438.05 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 12 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,206,026 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 894 | $18.15 | $16,226.10 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 11 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 9,682 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 90,943 | $18.15 | $1,650,615.45 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 10 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,058,604 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 27, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 45,709 | $18.15 | $829,618.35 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 9 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,637,302 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.00 to $18.445 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 28,583 | $18.48 | $528,213.84 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 8 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,241,973 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 710 | $18.48 | $13,120.80 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 7 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 10,576 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 72,310 | $18.48 | $1,336,288.80 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 6 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,149,547 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 24, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 36,345 | $18.48 | $671,655.60 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 5 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,683,011 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.1272 to $19.035 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 15,148 | $19.19 | $290,690.12 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 4 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,270,556 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 377 | $19.19 | $7,234.63 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 3 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,286 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 38,322 | $19.19 | $735,399.18 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,221,857 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 19,261 | $19.19 | $369,618.59 |
DisclosureSEC source: 0001577014-26-000004 · form4-04272026_100429.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,719,356 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.00 to $19.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 59,663 | $19.68 | $1,174,167.84 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 16 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,285,704 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,485 | $19.68 | $29,224.80 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 15 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 11,663 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 150,942 | $19.68 | $2,970,538.56 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 14 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,260,179 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 22, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 75,866 | $19.68 | $1,493,042.88 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 13 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,738,617 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F9 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.05 to $20.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 605 | $20.05 | $12,130.25 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 12 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,345,367 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 15 | $20.05 | $300.75 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 11 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,148 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,530 | $20.05 | $30,676.50 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 10 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,411,121 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 769 | $20.05 | $15,418.45 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 9 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,814,483 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $20.04 to $20.0829 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 56,228 | $19.51 | $1,097,008.28 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 8 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,345,972 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,398 | $19.51 | $27,274.98 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 7 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 13,163 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 142,253 | $19.51 | $2,775,356.03 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 6 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,412,651 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 71,499 | $19.51 | $1,394,945.49 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 5 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,815,252 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.035 to $20.0301 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 56,368 | $20.06 | $1,130,742.08 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 4 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,402,200 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,401 | $20.06 | $28,104.06 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 3 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 14,561 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 142,604 | $20.06 | $2,860,636.24 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 5,554,904 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 71,676 | $20.06 | $1,437,820.56 |
DisclosureSEC source: 0001577014-26-000002 · form4-04222026_100417.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,886,751 F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.88 to $20.354 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | Not disclosed Strike: $33.20 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 10 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 2,500 | Not disclosed Strike: $48.30 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 9 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,920 | Not disclosed Strike: $61.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 8 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,920 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 1,500 | Not disclosed Strike: $265.90 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 7 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 5,200 | Not disclosed Strike: $190.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 6 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,200 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Issuer Option that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | Disposition to issuerStock Option (right to buy) · Derivative | 3,000 | Not disclosed Strike: $3.87 | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · derivative · entry 5 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Cash Amount (each, an "In-The-Money Option"), became fully vested and was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share of Common Stock underlying such In-the-Money Option at the Effective Time by (y) the number of shares of Common Stock underlying such In-the-Money Option at the Effective Time. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 60 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · nonDerivative · entry 3 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F5 · ownership.nature: The shares are held directly by Atlas Venture Associates Opportunity I, L.P. ("AVAO LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVAO LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 116,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 09, 2026 Filed Feb 9, 2026 22:41 UTC | Generation Bio Co. GBIO · Entity 67174 | OtherCommon Stock | 711,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-012195 · tm265471-10_4seq1.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · kind: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"), F2 · price: (continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F3 · ownership.nature: The shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-015956 · form4-06062025_040601.xml · derivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: This option was granted on June 4, 2025. The shares underlying the option will fully vest on the earlier of: June 4, 2026 and the date of Generation Bio's 2026 annual meeting of stockholders. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:39 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0000950170-25-081356 · ownership.xml · derivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 1,111,111 | $13.50 | $14,999,998.50 |
DisclosureSEC source: 0001415889-25-002264 · form4-01292025_040102.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,958,427 F1 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 22:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 72 | $33.10 | $2,383.20 |
DisclosureSEC source: 0001415889-24-027119 · form4-11182024_101143.xml · nonDerivative · entry 4 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 847,316 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 22:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 123 | $33.10 | $4,071.30 |
DisclosureSEC source: 0001415889-24-027119 · form4-11182024_101143.xml · nonDerivative · entry 3 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,458,568 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 22:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 4 | $33.10 | $132.40 |
DisclosureSEC source: 0001415889-24-027119 · form4-11182024_101143.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,962 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securities held by AVA XI LP, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 22:31 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 583 | $33.10 | $19,297.30 |
DisclosureSEC source: 0001415889-24-027119 · form4-11182024_101143.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,697,508 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.96 to $33.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of such securities held by Atlas Venture Fund XI, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | Generation Bio Co. GBIO · Entity 67174 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001415889-24-016187 · form4-06102024_040621.xml · derivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2024. The shares underlying the option will fully vest on the earlier of: June 6, 2025 and the date of Generation Bio's 2025 annual meeting of stockholders. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 25,133 | $0.00 Strike: $31.53 | $0.00 |
DisclosureSEC source: 0000950170-24-064725 · ownership.xml · derivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,133 Underlying: Common Stock · 25,133 shares Expires 2034-05-21 F1 · derivative.exercise_date: This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service. F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 17,099 | $30.05 | $513,824.95 |
DisclosureSEC source: 0001415889-24-006766 · form4-03052024_100311.xml · nonDerivative · entry 2 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 847,388 F4 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund II, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 · ownership.nature: The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associates Opportunity II, LLC ("AVAO II LLC") is the general partner of AVAO II LP. The Reporting Person is a member of AVAO II LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF II, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 29,435 | $30.05 | $884,521.75 |
DisclosureSEC source: 0001415889-24-006766 · form4-03052024_100311.xml · nonDerivative · entry 1 Rhodes Jason P · CIK 0001577014 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,458,691 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 10, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The reporting person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.